Lutathera from Novartis is indicated to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, which include foregut, midgut and handout neuroendocrine tumors in adults. The drug was the focus of a recent presentation World Congress on Gastrointestinal Cancer 2021 where Dr. Jonathan R. Strosberg, presented positive survival data concerning the drug. Strosberg is the head of the Neuroendocrine Tumor…